<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006797" GROUP_ID="LIVER" ID="457307020212382600" MERGED_FROM="" MODIFIED="2009-11-10 12:58:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="31" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-11-10 12:52:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2009-11-06 14:29:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases</TITLE>
<CONTACT>
<PERSON ID="EDD1B9F582E26AA20135ECF1AB0B3200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kurinchi Selvan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gurusamy</LAST_NAME>
<SUFFIX>MBBS MS MRCS</SUFFIX>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>kurinchi2k@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+44 (0)7944 629303</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>University Department of Surgery</DEPARTMENT>
<ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION>
<ADDRESS_1>9th Floor, Royal Free Hospital</ADDRESS_1>
<ADDRESS_2>Pond Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>NW3 2QG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 830 2757</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 830 2688</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-11-10 12:55:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="EDD1B9F582E26AA20135ECF1AB0B3200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kurinchi Selvan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gurusamy</LAST_NAME>
<SUFFIX>MBBS MS MRCS</SUFFIX>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>kurinchi2k@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+44 (0)7944 629303</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>University Department of Surgery</DEPARTMENT>
<ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION>
<ADDRESS_1>9th Floor, Royal Free Hospital</ADDRESS_1>
<ADDRESS_2>Pond Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>NW3 2QG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 830 2757</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 830 2688</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="44AB7CD682E26AA200DA2AF3CEA036F4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rajarajan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ramamoorthy</LAST_NAME>
<SUFFIX>MBBS, MS, Dip.NB, MRCS</SUFFIX>
<POSITION>Senior Clinical Fellow</POSITION>
<EMAIL_1>drrajarajan@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University Department of Surgery</DEPARTMENT>
<ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW3 2QG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 830 2757</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 830 2688</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6A0185B182E26AA2019232D7A62B6136" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Charles</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Imber</LAST_NAME>
<SUFFIX>FRCS</SUFFIX>
<POSITION>Consultant Surgeon</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Surgery</DEPARTMENT>
<ORGANISATION>University College London Hospital</ORGANISATION>
<ADDRESS_1>235 Euston Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW1 2BU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44-7967322106</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0BFE5DB682E26AA200426E053932D8DE" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Brian</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Davidson</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of HPB and Liver Transplant Surgery</POSITION>
<EMAIL_1>b.davidson@medsch.ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University Department of Surgery</DEPARTMENT>
<ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION>
<ADDRESS_1>Pond Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>NW3 2QG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 830 2757</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 830 2688</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-11-10 12:52:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="6" MONTH="9" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="9" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-09-17 12:29:26 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2009-09-17 16:34:04 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<INTERNAL_SOURCES MODIFIED="2008-07-19 14:27:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<SOURCE MODIFIED="2008-07-19 14:27:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-09-17 16:34:04 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<SOURCE MODIFIED="2009-09-17 16:34:04 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-10 00:15:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2009-10-29 16:27:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2009-10-29 16:20:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">No evidence from randomised clinical trials for optimal management of patients with large bowel cancer spread to lymph glands draining the liver</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-29 16:27:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Nearly a third of patients with large bowel cancers (colorectal cancer) spread to the liver (liver metastases) within five years of diagnosis of bowel cancer. The affected part of the liver can be removed surgically in a quarter of such patients who develop liver spread from bowel cancer. About a seventh of these patients, in whom the affected part of the liver is suitable for removal, develop cancer involvement of lymph glands draining the liver (hepatic lymph node). Such patients are associated with poor survival even after removal of the affected part of the liver and the involved nodes. This Cochrane review attempted to answer the question of whether removing the part of the liver is better than other forms of treatment (such as no treatment, chemotherapy, heat destructive therapy using radiofrequency waves, ie, radiofrequency ablation) in such patients but did not find any randomised clinical trial addressing the issue. Currently, there is no evidence from randomised clinical trials for optimal management of these patients. High quality randomised clinical trials are feasible and are necessary to determine the optimal management of patients with colorectal liver metastases with hepatic node involvement.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-10 00:02:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2008-07-27 17:18:16 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>Involvement of hepatic lymph node in patients with colorectal liver metastases is associated with poor prognosis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-27 17:18:43 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>To determine the benefits and harms of curative liver resection with lymphadenectomy versus other treatments for colorectal liver metastases with hepatic node involvement.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-29 16:16:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, the <I>Cochrane Central Register of Controlled Trials (CENTRAL)</I> in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE</I>, <I>Science Citation Index Expanded,</I> and <I>LILACS</I> until September 2009 for identifying the randomised trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-08-29 17:09:15 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>We considered only randomised clinical trials (irrespective of language, blinding, or publication status) comparing liver resection (alone or in combination with radiofrequency ablation or cryoablation) versus other treatments (neo-adjuvant chemotherapy, chemotherapy, or radiofrequency ablation) in patients with colorectal liver metastases with hepatic node involvement.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-09-17 16:35:01 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>Two authors independently identified trials for inclusion. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-10-29 16:19:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to identify any randomised clinical trial fulfilling the inclusion criteria of this review. We were also unable to identify any quasi-randomised or cohort studies, which could meaningfully answer this important issue.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-10 00:02:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>There is no evidence in the literature to assess the role of surgery versus other treatments for patients with colorectal liver metastases with hepatic node involvement. High quality randomised clinical trials are feasible and are necessary to determine the optimal management of patients with colorectal liver metastases with hepatic node involvement.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-10 00:15:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2009-11-10 00:04:20 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Colorectal cancer is the third commonest malignancy in the United Kingdom with an estimated 34,000 patients diagnosed every year (<LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>). It is the second most common cause of cancer mortality (next only to lung cancer) accounting for nearly a tenth of cancer deaths in UK (<LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>) and for 1 in 40 deaths from all causes (<LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>). Nearly 16,000 people die annually due to colorectal cancer (<LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>).</P>
<P>Nearly a third of patients with colorectal cancers develop spread to the liver (liver metastases) within five years (<LINK REF="REF-Manfredi-2006" TYPE="REFERENCE">Manfredi 2006</LINK>). Of these metastatic deposits, 20% to 32% are resectable (<LINK REF="REF-Adam-2001" TYPE="REFERENCE">Adam 2001</LINK>; <LINK REF="REF-Tepper-2003" TYPE="REFERENCE">Tepper 2003</LINK>; <LINK REF="REF-Adam-2004" TYPE="REFERENCE">Adam 2004</LINK>). The five-year survival after liver resection varies between 16% and 30% (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>; <LINK REF="REF-Ambiru-1999" TYPE="REFERENCE">Ambiru 1999</LINK>; <LINK REF="REF-Adam-2004" TYPE="REFERENCE">Adam 2004</LINK>; <LINK REF="REF-Mutsaerts-2005" TYPE="REFERENCE">Mutsaerts 2005</LINK>; <LINK REF="REF-Vassiliou-2007" TYPE="REFERENCE">Vassiliou 2007</LINK>). Cancer seed to hepatic lymph nodes identified during liver resection is considered as a poor prognostic factor (<LINK REF="REF-Rodgers-2000" TYPE="REFERENCE">Rodgers 2000</LINK>; <LINK REF="REF-Abdalla-2006" TYPE="REFERENCE">Abdalla 2006</LINK>), with five-year survival after liver resection varying between 0% and 4.3% (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>; <LINK REF="REF-Jaeck-2002" TYPE="REFERENCE">Jaeck 2002</LINK>; <LINK REF="REF-Laurent-2004" TYPE="REFERENCE">Laurent 2004</LINK>). In studies of patients with liver metastases who underwent routine lymphadenectomy, about 14% to 15% of patients with nodes (draining the liver) considered uninvolved macroscopically are infiltrated by tumour cells microscopically (<LINK REF="REF-Jaeck-2002" TYPE="REFERENCE">Jaeck 2002</LINK>; <LINK REF="REF-Laurent-2004" TYPE="REFERENCE">Laurent 2004</LINK>). Patients who have involvement of common hepatic and coeliac artery nodes (considered as group 2 nodes) (<LINK REF="REF-Jaeck-2003" TYPE="REFERENCE">Jaeck 2003</LINK>) have been reported to have a poorer prognosis than the patients with involvement of hepato-duodenal or retro-pancreatic group of nodes (considered as group 1 nodes) (<LINK REF="REF-Jaeck-2003" TYPE="REFERENCE">Jaeck 2003</LINK>). Approximately half of the microscopic disease is in the hepato-duodenal and the retro-pancreatic group (<LINK REF="REF-Jaeck-2003" TYPE="REFERENCE">Jaeck 2003</LINK>) and therefore amenable to radical lymphadenectomy.</P>
<P>The mechanism for development of hepatic node involvement is not known, nor whether they represent spread from the liver metastases (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>) or the primary bowel cancer. In people with positive nodes, after adjusting for different factors, such as tumour number (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>; <LINK REF="REF-Kokudo-1998" TYPE="REFERENCE">Kokudo 1998</LINK>; <LINK REF="REF-Jaeck-2002" TYPE="REFERENCE">Jaeck 2002</LINK>; <LINK REF="REF-Tocchi-2004" TYPE="REFERENCE">Tocchi 2004</LINK>), size (<LINK REF="REF-Kokudo-1998" TYPE="REFERENCE">Kokudo 1998</LINK>; <LINK REF="REF-Jaeck-2002" TYPE="REFERENCE">Jaeck 2002</LINK>; <LINK REF="REF-Tocchi-2004" TYPE="REFERENCE">Tocchi 2004</LINK>), distribution (<LINK REF="REF-Jaeck-2002" TYPE="REFERENCE">Jaeck 2002</LINK>; <LINK REF="REF-Tocchi-2004" TYPE="REFERENCE">Tocchi 2004</LINK>), and surgical resection margin (<LINK REF="REF-Kokudo-1998" TYPE="REFERENCE">Kokudo 1998</LINK>), survival after liver resection are similar to those in patients with unresectable colorectal metastasis who underwent hepatic infusion chemotherapy (<LINK REF="REF-Bennett-2005" TYPE="REFERENCE">Bennett 2005</LINK>; <LINK REF="REF-Kemeny-2005" TYPE="REFERENCE">Kemeny 2005</LINK>). Median survival after systemic chemotherapy with leucovorin, 5-fluorouracil, oxaliplatin, and irinotecan has been recently reported to be around 20 months (<LINK REF="REF-Kemeny-2006" TYPE="REFERENCE">Kemeny 2006</LINK>; <LINK REF="REF-Falcone-2007" TYPE="REFERENCE">Falcone 2007</LINK>) with an estimated three-year survival of about 10% (<LINK REF="REF-Kemeny-2006" TYPE="REFERENCE">Kemeny 2006</LINK>). In light of this, hepatic node involvement detected pre-operatively or during surgery is generally considered a contra-indication for liver resection for liver secondaries from colorectal primary (<LINK REF="REF-Irie-1999" TYPE="REFERENCE">Irie 1999</LINK>; <LINK REF="REF-Imamura-2001" TYPE="REFERENCE">Imamura 2001</LINK>). With the improving results of resection of extra-hepatic disease (five-year survival of 18%) following neo-adjuvant chemotherapy, ie, chemotherapy followed by surgery followed by chemotherapy (<LINK REF="REF-Adam-2001" TYPE="REFERENCE">Adam 2001</LINK>), hepatic node involvement as a contra-indication for liver resection for colorectal liver metastases requires to be reconsidered. Regional nodal involvement in other cancers, such as oesophageal cancers (<LINK REF="REF-Tsuchiya-2002" TYPE="REFERENCE">Tsuchiya 2002</LINK>; <LINK REF="REF-Yano-2006" TYPE="REFERENCE">Yano 2006</LINK>) and rectal cancers (<LINK REF="REF-Onaitis-2001" TYPE="REFERENCE">Onaitis 2001</LINK>; <LINK REF="REF-Stipa-2004" TYPE="REFERENCE">Stipa 2004</LINK>), have been treated with pre-operative chemotherapy in order to down-stage the disease, which may improve the median survival (<LINK REF="REF-Tsuchiya-2002" TYPE="REFERENCE">Tsuchiya 2002</LINK>). Down-staging the disease in patients with colorectal liver metastases associated with hepatic nodal involvement may improve the survival.</P>
<P>Besides the heterogeneity arising due to the involvement of different groups of nodes, other factors such as the method used for determining nodal involvement, the number of nodes examined, whether routine or selective lymphadenectomy was performed may contribute to the heterogeneity in the patients included in the studies. In spite of this clinical heterogeneity, the prognosis for patients with hepatic node involvement who underwent liver resection is poor (<LINK REF="REF-Gurusamy-2008" TYPE="REFERENCE">Gurusamy 2008</LINK>) and the optimal management of these patients remains unclear. Recently, there have been reports that radiofrequency ablation for colorectal metastases is associated with reasonable survival even in patients with colorectal liver metastases deemed unresectable (<LINK REF="REF-Oshowo-2003" TYPE="REFERENCE">Oshowo 2003</LINK>; <LINK REF="REF-Leblanc-2008" TYPE="REFERENCE">Leblanc 2008</LINK>). Radiofrequency ablation has been suggested as an alternative to surgical resection even in patients with resectable disease (<LINK REF="REF-Mulier-2008" TYPE="REFERENCE">Mulier 2008</LINK>).</P>
<P>There has been no meta-analysis or systematic review of randomised clinical trials comparing potentially curative liver resection with lymphadenectomy and other potentially curative or palliative modalities of treatment of colorectal liver metastases with hepatic node involvement.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-07-19 21:10:48 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>To determine the benefits and harms of potentially curative liver resection with lymphadenectomy versus other potentially curative or palliative treatments of patients with colorectal liver metastases with hepatic node involvement.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-10 00:10:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2009-11-10 00:05:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2009-10-29 16:30:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We considered all randomised clinical trials (irrespective of language, blinding, publication status, or sample size) for inclusion.</P>
<P>Quasi-randomised studies (where the method of allocating participants to a treatment are not strictly random, for example, date of birth, hospital record number, alternation) were not included regarding assessment of benefit but were considered for inclusion regarding assessment of harm.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-17 16:35:38 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>Patients with colorectal liver metastases, who are found to have hepatic node involvement (irrespective whether group 1 or group 2 nodes) and otherwise resectable (however defined by authors).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-29 17:15:53 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>We planned to study the following interventions.</P>
<OL>
<LI>Potentially curative surgical liver resection (liver resection where all macroscopic disease is removed) with lymphadenectomy versus other potentially curative (radiofrequency ablation) or palliative treatment (where potentially curative surgical resection or radiofrequency ablation is not possible; including chemotherapy and radiofrequency ablation).</LI>
<LI>Potentially curative surgical resection or ablation with lymphadenectomy or lymph node ablation as part of neo-adjuvant chemotherapy versus palliative treatment.</LI>
</OL>
<P>We planned to allow co-interventions if carried out equally in the trial groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-10 00:05:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-11-10 00:05:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>Mortality</LI>
<OL>
<LI>Proportion dead after one, three, five, and ten years.</LI>
<LI>Estimated median survival.</LI>
<LI>Hazard ratio for death.</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-11-10 00:05:50 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>Proportion with recurrence of liver metastases (for comparison of surgery, radiofrequency ablation, and cryoablation).</LI>
<LI>Disease-free survival.</LI>
<LI>Treatment-related morbidity (surgery - 30-day mortality, bile leak, lymphorrhoea, abdominal collections requiring treatment, wound related complications, such as wound infection, wound dehiscence; chemotherapy - systemic effects, such as bone marrow suppression, nausea, vomiting, diarrhoea; hepatic infusion chemotherapy - systemic adverse effects of chemotherapy and other toxicities, such as peptic ulceration, chemical hepatitis, and biliary sclerosis (<LINK REF="REF-Cohen-2003" TYPE="REFERENCE">Cohen 2003</LINK>)).</LI>
<LI>Blood transfusion requirements.</LI>
<LI>Total hospital stay.</LI>
<LI>Quality of life (however defined by authors).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-10 00:06:25 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>), the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE</I>, <I>Science Citation Index Expanded</I> (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>) and <I>LILACS</I> (<LINK REF="REF-Clark-2002" TYPE="REFERENCE">Clark 2002</LINK>). We have given the search strategies in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> with the time span for the searches. The last search was performed on the 6<SUP>th</SUP> of September 2009. We also searched the reviews of treatment of colorectal liver metastases for references to identify relevant trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-10 00:10:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial selection and extraction of data</HEADING>
<P>Two authors (KSG and RR), independently of each other, searched for trials and planned to group the identified trials into included or excluded, and to list the latter with reasons for the exclusion.</P>
<P>KSG and RR planned to independently extract the following data.</P>
<OL>
<LI>Year and language of publication.</LI>
<LI>Country.</LI>
<LI>Year of study.</LI>
<LI>Inclusion and exclusion criteria.</LI>
<LI>Method of diagnosing nodal involvement (radiological, laparoscopic or open surgical).</LI>
<LI>Method of confirmation of nodal involvement (histopathology, immunocytochemistry).</LI>
<LI>Synchronous or metachronous metastases.</LI>
<LI>Mean number of tumours.</LI>
<LI>Mean size of tumours.</LI>
<LI>Unilobar or bilobar metastases.</LI>
<LI>First resection or repeat liver resection.</LI>
<LI>Pre-operative chemotherapy.</LI>
<LI>Post-operative chemotherapy.</LI>
<LI>Operating time.</LI>
<LI>Other co-interventions (such as portal vein embolization).</LI>
<LI>Outcomes (mentioned above).</LI>
<LI>Risk of bias in trials (described below).</LI>
</OL>
<P>We planned to seek any unclear or missing information by contacting the authors of the individual trials. If there was any doubt whether the trials share the same patients - completely or partially (by identifying common authors and centres), we planned to contact the authors of the trials to clarify whether the trial report had been duplicated.</P>
<P>We resolved any differences in opinion through discussion or arbitration of the third author (BRD).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias</HEADING>
<P>We planned to assess the risk of bias in the trials independently, without masking of the trial names. We planned to follow the instructions given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and the <I>Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>). Due to the risk of biased overestimation of intervention effects in randomised trials with inadequate methodological quality (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), we planned to look at the influence of methodological quality of the trials on the results by evaluating the reported randomisation and follow-up procedures in each trial. If information was not available in the published trial, we planned to contact the trial authors in order to assess the trials correctly.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<UL>
<LI>Low risk of bias (the methods used is either adequate (eg, computer generated random numbers, table of random numbers) or unlikely to introduce confounding).</LI>
<LI>Uncertain risk of bias ( there is insufficient information to assess whether the method used is likely to introduce confounding).</LI>
<LI>High risk of bias (the method used (eg, quasi-randomised trials) is improper and likely to introduce confounding).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias (the method used (eg, central allocation) is unlikely to induce bias on the final observed effect).</LI>
<LI>Uncertain risk of bias (there is insufficient information to assess whether the method used is likely to induce bias on the estimate of effect).</LI>
<LI>High risk of bias (the method used (eg, open random allocation schedule) is likely to induce bias on the final observed effect).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>It is not possible to blind the health-care provider (surgeons or radiologists or oncologists) to the groups. However, it is possible to blind the patients (for comparisons such as liver resection versus open radiofrequency ablation) and the outcome assessors. <B>
<I>
<BR/>
</I>
</B>
</P>
<UL>
<LI>Low risk of bias, if the patients (whenever possible) and outcome assessors were blinded and the method of blinding was described.</LI>
<LI>Uncertain risk of bias, if the patients (whenever possible) and outcome assessors were blinded and the method of blinding was not described.</LI>
<LI>High risk of bias, if the patients (whenever possible) or outcome assessors were not blinded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias (the underlying reasons for missingness are unlikely to make treatment effects departure from plausible values, or proper methods have been employed to handle missing data).</LI>
<LI>Uncertain risk of bias (there is insufficient information to assess whether the missing data mechanism in combination with the method used to handle missing data is likely to induce bias on the estimate of effect).</LI>
<LI>High risk of bias (the crude estimate of effects (eg, complete case estimate) will clearly be biased due to the underlying reasons for missingness, and the methods used to handle missing data are unsatisfactory).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias (the trial protocol is available and all of the trial's pre-specified outcomes that are of interest in the review have been reported or similar or all of the primary outcomes in this review have been reported).</LI>
<LI>Uncertain risk of bias (there is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting).</LI>
<LI>High risk of bias (not all of the primary outcomes in this review have been reported and not all of the trial's pre-specified outcomes that are of interest in the review have been reported).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline imbalance</HEADING>
<UL>
<LI>Low risk of bias (there was no baseline imbalance in important characteristics).</LI>
<LI>Uncertain risk of bias (the baseline characteristics were not reported).</LI>
<LI>High risk of bias (there was a baseline imbalance due to chance or due to imbalanced exclusion after randomisation).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Early stopping</HEADING>
<UL>
<LI>Low risk of bias (sample size calculation was reported and the trial was not stopped or the trial was stopped early by a formal stopping rule at a point where the likelihood of observing an extreme intervention effect due to chance was low).</LI>
<LI>Uncertain risk of bias (sample size calculations were not reported and it is not clear whether the trial was stopped early or not).</LI>
<LI>High risk of bias (the trial was stopped early due to an informal stopping rule or the trial was stopped early by a formal stopping rule at a point where the likelihood of observing an extreme intervention effect due to chance was high).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Academic bias</HEADING>
<UL>
<LI>Low risk of bias (the author of the trial has not conducted previous trials addressing the same interventions).</LI>
<LI>Uncertain risk of bias (It is not clear if the author has conducted previous trials addressing the same interventions).</LI>
<LI>High risk of bias (the author of the trial has conducted previous trials addressing the same interventions).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Source of funding bias</HEADING>
<UL>
<LI>Low risk of bias (the trial's source(s) of funding did not come from any parties that might have conflicting interest (eg, instrument or drug manufacturer).</LI>
<LI>Uncertain risk of bias (the source of funding was not clear).</LI>
<LI>High risk of bias (the trial was funded by an instrument or drug manufacturer).</LI>
</UL>
<P>We considered trials to be of low risk of bias if we assessed them to have low risk of bias in all the above domains.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical methods</HEADING>
<P>We planned to perform the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2009" TYPE="REFERENCE">Gluud 2009</LINK>) using the software package RevMan 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). For dichotomous variables, we planned to calculate the risk ratio with 95% confidence interval. For continuous variables, we planned to calculate the mean difference (for outcomes like hospital stay) and standardised mean difference (for outcomes like patient quality of life where different scales can be used). For calculation of time to event outcomes such as survival or recurrence, we planned to extract the logarithm of hazard ratios (ln(HR)) and the standard error (SE) of ln(HR) using the methods described by Parmar et al (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>) using the excel sheet provided by Tierney et al (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). We planned to use a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). In case of discrepancy between the two models we planned to report both results; otherwise we planned to report only the results from the fixed-effect model. We planned to explore heterogeneity using a chi-squared test with significance set at P value 0.10, and measure the quantity of heterogeneity by I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>) set at 30%.</P>
<P>We planned to perform the analysis on an intention-to-treat analysis (<LINK REF="REF-Newell-1992" TYPE="REFERENCE">Newell 1992</LINK>) whenever possible. Otherwise, we planned to adopt the 'available case analysis'. In case we found 'zero-event' trials for outcomes that are statistically significant without including the 'zero-event' trials, we planned to perform a sensitivity analysis with and without empirical continuity correction factors as suggested by Sweeting et al (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). We also planned to report the risk difference if the results were different from risk ratio.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We planned to perform subgroup analyses for trials with low risk of bias compared to those with high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bias exploration</HEADING>
<P>We planned to use a funnel plot to explore bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>). We planed to perform linear regression approach described by Egger et al to determine the funnel plot asymmetry (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-09-06 13:48:48 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<STUDY_DESCRIPTION MODIFIED="2009-09-06 13:48:48 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>We identified a total of 3986 references through electronic searches of <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I> and the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I> (n = 170), <I>MEDLINE</I> (n = 1358), <I>EMBASE</I> (n = 1772), <I>Science Citation Index Expanded</I> (n = 686) and <I>LILACS</I> (n = 0). We excluded 906 duplicates. It was clear from reading titles and abstracts that none of the remaining 3080 references were randomised clinical trials. Although we would have excluded quasi-randomised trials for survival, we searched for any quasi-randomised trial in order to calculate the sample size and outcomes that can be used for any new randomised clinical trial. We were not able to identify any quasi-randomised study also from the retrieved references.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-19 14:25:16 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>None of the studies identified through the search strategy qualified for inclusion in this review. We were also unable to identify any cohort studies or any case-control studies that could meaningfully try to answer the questions posed in this systematic review.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-19 14:25:28 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<P>None of the studies identified through the search strategy qualified for this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-10 00:13:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The involvement of hepatic lymph node in patients with colorectal liver metastases is associated with poor prognosis irrespective of whether these are evident macroscopically or microscopically (<LINK REF="REF-Gurusamy-2008" TYPE="REFERENCE">Gurusamy 2008</LINK>). Some surgeons consider involvement of hepatic lymph node to be a contra-indication for liver resection (<LINK REF="REF-Irie-1999" TYPE="REFERENCE">Irie 1999</LINK>; <LINK REF="REF-Imamura-2001" TYPE="REFERENCE">Imamura 2001</LINK>). This review was undertaken to address the issue of optimal management of such patients.</P>
<P>None of the studies identified through the search strategy qualified for this review. We were also unable to identify non-randomised controlled studies (where the controls were similar in characteristics to the liver resection group), which could give information to facilitate the design of a randomised clinical trial.</P>
<P>Traditionally liver resection has offered better survival than other treatments for colorectal liver metastases. However, this was before the advent of the new modalities of treatment. Now the new modalities of treatment are reserved for patients who are not eligible for surgery. Thus, a fair comparison between surgical resection and other new modalities is not possible as surgical resection is performed in patients with favourable features, and the other treatments are performed in patients with unfavourable features. There is ethical dilemma in such situations. However, a previous review by our group showed that involvement of hepatic lymph node in patients with colorectal liver metastases is associated with poor prognosis even after liver resection combined with lymphadenectomy (<LINK REF="REF-Gurusamy-2008" TYPE="REFERENCE">Gurusamy 2008</LINK>). Thus, there seems to be no ethical dilemma for the surgeon in randomising such patients to resection versus other treatments.</P>
<P>We considered various comparisons for a randomised clinical trial on surgical resection. One possible comparison is the comparison of neo-adjuvant chemotherapy plus surgical resection (chemotherapy followed by surgery followed by chemotherapy) versus chemotherapy alone in patients with colorectal liver metastases with hepatic node involvement. Regional nodal involvement in other cancers, such as oesophageal cancers (<LINK REF="REF-Tsuchiya-2002" TYPE="REFERENCE">Tsuchiya 2002</LINK>; <LINK REF="REF-Yano-2006" TYPE="REFERENCE">Yano 2006</LINK>) and rectal cancers (<LINK REF="REF-Onaitis-2001" TYPE="REFERENCE">Onaitis 2001</LINK>; <LINK REF="REF-Stipa-2004" TYPE="REFERENCE">Stipa 2004</LINK>), have been treated with pre-operative chemotherapy for down-staging the disease, which may improve the median survival (<LINK REF="REF-Tsuchiya-2002" TYPE="REFERENCE">Tsuchiya 2002</LINK>). Down-staging the disease in patients with colorectal liver metastases associated with hepatic nodal involvement may improve the survival. However, this would necessitate a pre-operative diagnosis of nodal involvement and, therefore, only patients with macroscopic positive hepatic lymph nodes (available to biopsy) could be included in this trial. The incidence of macroscopically positive hepatic lymph nodes is 4.8% in patients with otherwise resectable colorectal hepatic metastases (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>). Approximately 50% of the patients with hepatic node disease are alive at one year (<LINK REF="REF-Gurusamy-2008" TYPE="REFERENCE">Gurusamy 2008</LINK>). In order to demonstrate an improvement of median survival from 12 months to 18 months with a recruitment period of 24 months and an additional follow-up period of 24 months with an alpha error of 0.05 and a power of 80%, an overall sample size of 240 patients are required (120 patients in each group). However, in such a trial, there will be a high percentage of cross-over between the groups as patients, who progress in spite of chemotherapy in the surgery group and may no longer be resectable. It may also be unethical to refuse surgery for patients belonging to the chemotherapy group, whose disease has been down staged by chemotherapy. However, these patients could be considered for a longitudinal study involving surgical resection for patients responding to systemic chemotherapy. It is important that hepatic node involvement of the patients included in such a study is identified by histological examination rather than imaging since a significant proportion of patients considered to have hepatic node positive disease by computerised tomogram (CT scan) turned out to have no nodal involvement on histological examination (<LINK REF="REF-Beckurts-1997" TYPE="REFERENCE">Beckurts 1997</LINK>).</P>
<P>Another trial that can be performed is neo-adjuvant chemotherapy versus liver resection with hepatic lymphadenectomy (with or without post-operative chemotherapy) in hepatic node positive patients. Again, the patients included in the trial must have a histological confirmation of hepatic node involvement before randomisation. Some patients in the neo-adjuvant chemotherapy group may have cancer progression in spite of chemotherapy. Such patients may no longer have resectable cancer. Patients in the direct surgery group may be found to have unresectable cancer on laparotomy. It is likely that a proportion of patients in both groups would not undergo surgical resection. However, these patients should be included for all the outcomes on an intention-to-treat analysis, which will provide necessary information to perform a cost-utility analysis between neo-adjuvant chemotherapy and direct surgery. Blinding of health-care providers and patients is not possible in such a trial, and the trial is likely to suffer from high bias-risk for outcomes such as quality of life. However, the primary outcome of survival is likely to be free from bias due to lack of blinding (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>Another trial that can be performed is comparison of surgical resection versus radiofrequency ablation in this group of patients. Both groups can be combined with chemotherapy. Routine or selective lymph node dissection is likely to result in a higher morbidity than just liver resection. Radiofrequency ablation has been reported to provide a two-year survival of 75% and three-year survival of 50% of patients with unresectable colorectal liver metastases (<LINK REF="REF-Oshowo-2003" TYPE="REFERENCE">Oshowo 2003</LINK>; <LINK REF="REF-Leblanc-2008" TYPE="REFERENCE">Leblanc 2008</LINK>). Radiofrequency ablation is generally considered to be associated with lower morbidity than major liver resection. However, there are concerns about a higher recurrence rate after radiofrequency ablation than surgical resection (<LINK REF="REF-Sutherland-2006" TYPE="REFERENCE">Sutherland 2006</LINK>; <LINK REF="REF-Curley-2008" TYPE="REFERENCE">Curley 2008</LINK>). Considering the low survival after resection in patients with hepatic node positive colorectal liver metastases, radiofrequency ablation may provide an equivalent survival in these patients with lower morbidity. However, if percutaneous radiofrequency ablation is contemplated, it is important that hepatic node involvement is identified by histological examination as mentioned previously. Blinding of health-care providers (surgeon or radiologist) is not possible. Blinding of patients is possible only in a comparison of surgical resection versus open radiofrequency ablation and not in a trial comparing surgical resection and percutaneous radioablation (after confirmation of hepatic node involvement by CT guided biopsy). Although it is possible to blind the outcome assessors for all the outcomes, lack of patient blinding is likely to introduce bias in quality of life. However, a properly conducted trial is likely to provide a low-bias risk estimate of survival.</P>
<P>Another trial that we considered was that of surgical resection versus no treatment (no chemotherapy but palliation of symptoms such as pain, nausea, vomiting etc will be allowed) for this group of patients. Studies on the natural history of patients with colorectal liver metastases who did not undergo resection or chemotherapy show widely varying results from 10% one-year survival to 40% one-year survival in patients with disseminated metastases (<LINK REF="REF-Bengtsson-1981" TYPE="REFERENCE">Bengtsson 1981</LINK>; <LINK REF="REF-Wagner-1984" TYPE="REFERENCE">Wagner 1984</LINK>). This is in comparison with approximately 50% one year survival in the patients eligible for surgical resection (ie, good general medical condition and metastases confined to the liver or resectable extra-hepatic spread). Besides, there was no difference in the survival between patients who underwent chemotherapy and those who did not undergo chemotherapy after adjusting for the extent of the metastases in one of the studies (<LINK REF="REF-Wagner-1984" TYPE="REFERENCE">Wagner 1984</LINK>). However, these studies were conducted more than 25 years ago and we decided that a comparison of surgical resection versus no treatment might be unethical, given the recent advances in chemotherapy including oxaliplatin. Besides, it is unlikely that patients agree to participate in such a trial. Trials assessing neo-adjuvant chemotherapy plus surgical resection versus chemotherapy alone; neo-adjuvant chemotherapy versus surgical resection with or without post-operative chemotherapy; and/or surgical resection versus radiofrequency ablation (both groups may or may not have adjuvant chemotherapy) are likely to be ethical and patients may be more willing to participate in such trials.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-10 00:15:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-10 00:14:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>There is no evidence in the literature to assess the role of resection versus other treatments for patients with colorectal liver metastases with hepatic node involvement.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-10 00:15:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>High quality randomised clinical trials are feasible and are necessary to determine the optimal management of patients with colorectal liver metastases with hepatic node involvement. Such trials ought to be reported according to the Consort Statement (http://www.consort-statement.org).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-10-29 18:02:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To TC Mahendran, Chennai, India, who was the first surgical teacher of the first author.<BR/>To The Cochrane Hepato-Biliary Group for the support that they have provided.</P>
<P>Peer Reviewers: J Kleijnen, UK; P Wille-Jørgensen, Denmark. <BR/>Contact Editor: C Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-11-06 14:29:47 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-29 17:54:36 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>KS Gurusamy wrote the review and assessed the trials for inclusion. R Ramamoorthy independently assessed the trials for inclusion. C Imber and BR Davidson critically commented on the review, provided advice for improving the review and the design of the randomised clinical trials. All authors approved of the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-09-08 15:30:57 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>The interventions that will be included for this review have been clarified. The outcomes have now been classified into primary and secondary outcomes. The method of assessment of bias-risk has been updated in line with the methodology stated in the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-09 13:13:03 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<INCLUDED_STUDIES MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy"/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-09 13:13:03 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-09 13:13:03 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abdalla-2006" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Abdalla 2006" TYPE="JOURNAL_ARTICLE">
<AU>Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D</AU>
<TI>Improving resectability of hepatic colorectal metastases: expert consensus statement</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>10</NO>
<PG>1271-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adam-2001" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Adam 2001" TYPE="JOURNAL_ARTICLE">
<AU>Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al</AU>
<TI>Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>4</NO>
<PG>347-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adam-2004" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Adam 2004" TYPE="JOURNAL_ARTICLE">
<AU>Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al</AU>
<TI>Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival</TI>
<SO>Annals of Surgery</SO>
<YR>2004</YR>
<VL>240</VL>
<NO>4</NO>
<PG>644-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ambiru-1999" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Ambiru 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, et al</AU>
<TI>Hepatic resection for colorectal metastases: analysis of prognostic factors</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>5</NO>
<PG>632-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beckurts-1997" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Beckurts 1997" TYPE="JOURNAL_ARTICLE">
<AU>Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR</AU>
<TI>Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases</TI>
<SO>British Journal of Surgery</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>8</NO>
<PG>1081-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bengtsson-1981" MODIFIED="2009-09-26 07:31:09 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Bengtsson 1981" TYPE="JOURNAL_ARTICLE">
<AU>Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE</AU>
<TI>Natural history of patients with untreated liver metastases from colorectal cancer</TI>
<SO>American Journal of Surgery</SO>
<YR>1981</YR>
<VL>141</VL>
<NO>5</NO>
<PG>586-9</PG>
<IDENTIFIERS MODIFIED="2009-09-26 07:30:42 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<IDENTIFIER TYPE="PUBMED" VALUE="7223955"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2005" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Bennett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bennett JJ, Cao D, Posner MC</AU>
<TI>Determinants of unresectability and outcome of patients with occult colorectal hepatic metastases</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>1</NO>
<PG>64-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2002" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Clark 2002" TYPE="JOURNAL_ARTICLE">
<AU>Clark OA, Castro AA</AU>
<TI>Searching the Literatura Latino Americana e do Caribe em Ciencias da Saude (LILACS) database improves systematic reviews</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>112-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2003" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Cohen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AD, Kemeny NE</AU>
<TI>An update on hepatic arterial infusion chemotherapy for colorectal cancer</TI>
<SO>The Oncologist</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>6</NO>
<PG>553-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curley-2008" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Curley 2008" TYPE="JOURNAL_ARTICLE">
<AU>Curley SA</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>1</NO>
<PG>11-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-10-04 09:32:54 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falcone-2007" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Falcone 2007" TYPE="JOURNAL_ARTICLE">
<AU>Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al</AU>
<TI>Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>13</NO>
<PG>1670-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2009" MODIFIED="2009-11-09 13:13:03 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2009" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2009, Issue 4. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurusamy-2008" MODIFIED="2009-09-09 13:36:33 +0200" MODIFIED_BY="[Empty name]" NAME="Gurusamy 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gurusamy K, Imber C, Davidson BR</AU>
<TI>Management of the hepatic lymph nodes during resection of liver metastases from colorectal cancer - a systematic review</TI>
<SO>HPB Surgery</SO>
<YR>2008</YR>
<VL>2008</VL>
<PG>684150 (Electronic)</PG>
<IDENTIFIERS MODIFIED="2008-09-02 14:10:24 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<IDENTIFIER MODIFIED="2008-09-02 14:10:24 +0200" MODIFIED_BY="Sarah Louise Klingenberg" TYPE="DOI" VALUE="10.1155/2008/684150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008]</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Colloboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imamura-2001" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Imamura 2001" TYPE="JOURNAL_ARTICLE">
<AU>Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, et al</AU>
<TI>A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>11</NO>
<PG>3178-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irie-1999" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Irie 1999" TYPE="JOURNAL_ARTICLE">
<AU>Irie T, Itai Y, Hatsuse K, Mochizuki H</AU>
<TI>Does resection of small liver metastases from colorectal cancer improve survival of patients?</TI>
<SO>British Journal of Radiology</SO>
<YR>1999</YR>
<VL>72</VL>
<NO>855</NO>
<PG>246-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaeck-2002" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Jaeck 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, et al</AU>
<TI>Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>5</NO>
<PG>430-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaeck-2003" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Jaeck 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jaeck D</AU>
<TI>The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1007-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemeny-2005" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kemeny 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al</AU>
<TI>Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>22</NO>
<PG>4888-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemeny-2006" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kemeny 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al</AU>
<TI>Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>9</NO>
<PG>1395-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kokudo-1998" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kokudo 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kokudo N, Seki M, Ohta H, Azekura K, Ueno M, Sato T, et al</AU>
<TI>Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>8</NO>
<PG>706-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laurent-2004" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Laurent 2004" TYPE="JOURNAL_ARTICLE">
<AU>Laurent C, Sa CA, Rullier E, Smith D, Rullier A, Saric J</AU>
<TI>Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2004</YR>
<VL>198</VL>
<NO>6</NO>
<PG>884-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leblanc-2008" MODIFIED="2009-09-09 13:38:39 +0200" MODIFIED_BY="[Empty name]" NAME="Leblanc 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pelissier S, Evrard S</AU>
<TI>Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>2</NO>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macaskill-2001" MODIFIED="2009-10-04 09:32:54 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Macaskill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Macaskill P, Walter SD, Irwig L</AU>
<TI>A comparison of methods to detect publication bias in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>641-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manfredi-2006" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Manfredi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM</AU>
<TI>Epidemiology and management of liver metastases from colorectal cancer</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>244</VL>
<NO>2</NO>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulier-2008" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Mulier 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T</AU>
<TI>Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>1</NO>
<PG>144-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mutsaerts-2005" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Mutsaerts 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F</AU>
<TI>Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>2</NO>
<PG>178-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-1992" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Newell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newell DJ</AU>
<TI>Intention-to-treat analysis: implications for quantitative and qualitative research</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onaitis-2001" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Onaitis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, et al</AU>
<TI>Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience</TI>
<SO>Annals of Surgery</SO>
<YR>2001</YR>
<VL>233</VL>
<NO>6</NO>
<PG>778-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oshowo-2003" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Oshowo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I</AU>
<TI>Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases</TI>
<SO>The British Journal of Surgery</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>10</NO>
<PG>1240-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2009-10-04 10:04:39 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9921604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodgers-2000" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Rodgers 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers MS, McCall JL</AU>
<TI>Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review</TI>
<SO>The British Journal of Surgery</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>9</NO>
<PG>1142-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2009-09-09 13:39:39 +0200" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stipa-2004" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Stipa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stipa F, Zernecke A, Moore HG, Minsky BD, Wong WD, Weiser M, et al</AU>
<TI>Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection?</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>2</NO>
<PG>187-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutherland-2006" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Sutherland 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ</AU>
<TI>Radiofrequency ablation of liver tumors: a systematic review</TI>
<SO>Archives of Surgery</SO>
<YR>2006</YR>
<VL>141</VL>
<NO>2</NO>
<PG>181-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2009-10-04 09:21:57 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Sweeting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1351-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tepper-2003" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Tepper 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ</AU>
<TI>Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>19</NO>
<PG>3623-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2009-10-04 10:04:25 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17555582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tocchi-2004" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Tocchi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tocchi A, Mazzoni G, Brozzetti S, Miccini M, Cassini D, Bettelli E</AU>
<TI>Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>6</NO>
<PG>580-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuchiya-2002" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Tsuchiya 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya Y, Onda M, Sasajima K, Yamashita K, Nomura T, Makino H, et al</AU>
<TI>Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>3</NO>
<PG>226-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vassiliou-2007" MODIFIED="2008-09-02 14:23:08 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Vassiliou 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vassiliou I, Arkadopoulos N, Theodosopoulos T, Fragulidis G, Marinis A, Kondi-Paphiti A, et al</AU>
<TI>Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>9</NO>
<PG>1431-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-1984" MODIFIED="2009-09-26 07:32:29 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Wagner 1984" TYPE="JOURNAL_ARTICLE">
<AU>Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM</AU>
<TI>The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment</TI>
<SO>Annals of Surgery</SO>
<YR>1984</YR>
<VL>199</VL>
<NO>5</NO>
<PG>502-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="6721600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-2005" MODIFIED="2009-09-09 13:43:17 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2005" TYPE="OTHER">
<AU>Wood H, Rowan S, Quinn M, Cooper N</AU>
<TI>National Cancer Intelligence Centre, Office for National Statistics. Cancer incidence and mortality in the United Kingdom 2001-03</TI>
<SO>http://www.statistics.gov.uk/downloads/theme_health/UK_inc&amp;mort_final.xls</SO>
<YR>2005 (accessed on 9 September 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yano-2006" MODIFIED="2008-09-02 14:23:09 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Yano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, et al</AU>
<TI>Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus</TI>
<SO>Diseases of Esophagus</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>3</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2008-07-19 20:04:59 +0200" MODIFIED_BY="Kurinchi S Gurusamy"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-09-26 07:32:20 +0200" MODIFIED_BY="Kurinchi S Gurusamy" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-19 12:12:14 +0200" MODIFIED_BY="Kurinchi S Gurusamy"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-11-10 12:53:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2009-11-10 12:53:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2008-07-19 12:09:08 +0200" MODIFIED_BY="Kurinchi S Gurusamy">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-10 12:53:00 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Period</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy used</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(metasta* OR secondar* OR spread OR cancer OR carcinoma OR tumour Or tumor OR neoplasm) AND (colon Or colonic OR colorect* OR rectal OR rectum OR gut OR intestine OR bowel) AND (liver OR hepatic) AND (segmentectomy OR resection)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Wiley)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 3, 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Neoplasm Metastasis explode all trees in MeSH products<BR/>#2 metasta* OR secondar* OR spread OR cancer OR carcinoma OR tumour Or tumor OR neoplasm in All Fields in all products<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Intestine, Large explode all trees<BR/>#5 MeSH descriptor Colorectal Surgery explode all trees<BR/>#6 MeSH descriptor Intestinal Neoplasms explode all trees<BR/>#7 colon Or colonic OR colorect* OR rectal OR rectum OR gut OR intestine OR bowel<BR/>#8(#4 OR #5 OR #6 OR #7)<BR/>#9 MeSH descriptor Liver explode all trees<BR/>#10 MeSH descriptor Liver Neoplasms explode all trees<BR/>#11 MeSH descriptor Liver Diseases explode all trees<BR/>#12 liver OR hepatic<BR/>#13 (#9 OR #10 OR #11 OR #12)<BR/>#14 segmentectomy OR resection<BR/>#15 (#13 AND #14)<BR/>#16 MeSH descriptor Hepatectomy explode all trees<BR/>#17 (#15 OR #16)<BR/>#18 (#3 AND #8 AND #17)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Pubmed)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1951 to September 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>("Neoplasm Metastasis"[MeSH] OR metasta* OR secondar* OR spread OR cancer OR carcinoma OR tumour Or tumor OR neoplasm) AND (colon Or colonic OR colorect* OR rectal OR rectum OR gut OR intestine OR bowel OR "Intestine, Large"[MeSH] OR "Colorectal Surgery"[MeSH] OR "Intestinal Neoplasms"[MeSH]) AND ((("Liver"[MeSH] OR "Liver Neoplasms"[MeSH] OR "Liver Diseases"[MeSH] OR liver OR hepatic) AND (segmentectomy OR resection)) OR "Hepatectomy"[MeSH]) AND ((randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) AND humans [mh])</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (OvidSP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1974 to September 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 LIVER-METASTASIS#.DE. OR METASTASIS#.W..DE. OR metasta$ OR secondary$ OR spread OR cancer OR carcinoma OR tumour OR tumor OR neoplasm<BR/>2 COLORECTAL-CANCER#.DE. OR colon OR colonic OR colorect$ OR rectal OR rectum OR gut OR intestine OR bowel<BR/>3 liver OR hepatic<BR/>4 segmentectomy OR resection<BR/>5 3 AND 4<BR/>6 hepatectomy OR LIVER-RESECTION.DE.<BR/>7 5 OR 6<BR/>8 1 AND 2 AND 7<BR/>9 RANDOM$ OR FACTORIAL$ OR CROSSOVER$ OR CROSS ADJ OVER$ OR PLACEBO$ OR DOUBL$ ADJ BLIND$ OR SINGL$ ADJ BLIND$ OR ASSIGN$ OR ALLOCAT$ OR VOLUNTEER$ OR CROSSOVER-PROCEDURE#.MJ. OR DOUBLE-BLIND-PROCEDURE#.DE. OR SINGLE-BLIND-PROCEDURE#.DE. OR RANDOMIZED-CONTROLLED-TRIAL#.DE.<BR/>10 8 AND 9</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://apps.isiknowledge.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1970 to September 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1TS=(metasta* OR secondar* OR spread OR cancer OR carcinoma OR tumour Or tumor OR neoplasm)<BR/>#2 TS=(colon Or colonic OR colorect* OR rectal OR rectum OR gut OR intestine OR bowel)<BR/>#3 TS=(liver OR hepatic)<BR/>#4 TS=(segmentectomy OR resection)<BR/>#5 TS=(random* OR blind*OR placebo* OR meta-analysis)<BR/>#6 #5 AND #4 AND #3 AND #2 AND #1<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS (http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/<BR/>?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2009</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(((Pt randomised controlled trial OR Pt controlled clinical trial OR Mh randomised controlled trials OR random Mh allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (animal Ct AND NOT (Ct human and animal Ct)) OR (Former clinical Pt trial OR E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Placebos OR Mh OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw bad luck OR Tw aleator$) OR Mh research design) AND NOT (animal Ct AND NOT (Ct human and animal Ct)) OR (Ct comparative Former study OR E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (animal Ct AND NOT (Ct human and animal Ct)))) AND (liver OR hepato$ OR hepatic)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>